Skip to main content
OpenTrials
Completed

NCT Number: NCT00584454

Safety Evaluation of a Q-fever Vaccine, NDBR 105

The purpose of this study is to evaluate the safety of Q Fever vaccine, NDBR 105, and collect data on incidence of occupational Q Fever infection in at risk personnel.

Completed

Looking for future studies?

Notify Me

Key information

Age range

17 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

U.S. Army Medical Research Institute of Infectious Diseases

Fort Deterick, Maryland, 21702, United States

About this study

Study Objectives:

  • Continue to collect and assess safety data on Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105, and 2) Provide vaccine that potentially protects personnel at risk for occupational exposure to Q Fever and collect data on incidence of occupational Q Fever infection (subclinical and clinical) in immunized personnel.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years old, or if on active military duty, 17 years old.
  • Females of childbearing potential must agree to have a urine pregnancy test on the same day before receipt of skin test antigen AND vaccine. (Exception: documented hysterectomy or > three years of menopause.) The results must be negative.
  • Volunteer must be actively enrolled in the SIP
  • Volunteer must be considered at risk for exposure to C. burnetii.
  • Volunteer must sign and date the approved ICD and HIPAA Authorization.
  • Volunteer must have an up-to-date (within one year) medical history, physical examination, and laboratory tests on their charts and be medically cleared for participation by an Investigator. Examinations or tests may be repeated within one year at the discretion of the enrolling physician.
  • Volunteer must be willing to return for all follow-up visits.
  • Volunteer must agree to report any AEs which may or may not be associated with administration of the test article for at least 28 days after vaccination. All SAEs and UAEs will be reported for the duration of the volunteer's participation in the study (one year).

Exclusion criteria

  • Prior history of Q fever disease or vaccination.
  • Clinically significant abnormal lab results including evidence of Hepatitis C, Hepatitis B carrier state, or elevated liver function tests (two times the normal range or at the discretion of the PI).
  • Personal history of an immunodeficiency or current treatment with an immunosuppressive medication or autoimmune disease.
  • Confirmed HIV infection.
  • Heart valve disease: murmur with abnormal echocardiogram (if murmur is detected on examination, volunteer will be referred to cardiologist to rule out pathology.)
  • Positive pregnancy test or lactating female (females must agree to not become pregnant for three months after vaccination.)
  • Any known allergies to components of the vaccine.
  • Administration of another inactivated vaccine within 7 days or a live or IND vaccine within 28 days of Q fever vaccination.
  • Any unresolved AE resulting from a previous immunization.

Treatment and study plan

Q Fever Vaccine (NDBR 105

Biological

Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.

Primary outcomes

  1. The Adverse Reaction and Occupational Illness Endpoint Measurements in This Q Fever NDBR 105 Vaccine Study Will be Evaluated for All Intent-to-treat Volunteers.

    Time frame: AEs recorded through day 28 after vaccination; SAEs recorded through duration of study; Confirmed occupational illness recorded through duration of study

    Observe adverse reactions and occupational illness endpoint measurements 7 days follow-up after receipt of skin test antigen and 12 months of follow-up after receipt of vaccine

Sponsors and collaborators

Lead sponsor

U.S. Army Medical Research and Development Command

Fed

Registry information

Official study title

Continued Evaluation of the Safety of Q Fever Vaccine, Phase I, Inactivated, Freeze Dried, NDBR 105, in Those at Risk of Exposure to Coxiella Burnetii, A Phase 2 Study

Important dates

Study start
2006
Primary completion
2009
Study completion
2014
First posted
Jan 2, 2008
Registry last updated
Jan 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.